Telix Pharmaceuticals Limited (ASX: TLX), an Australian biopharmaceutical company, and GenesisCare, a company that provides integrated cancer care in Australia, announced on Monday that they have enrolled the first patient in the phase II ProstACT TARGET study of Telix's prostate cancer antibody therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients with a first recurrence of prostate-specific antigen (PSA) after initial therapy for prostate cancer.

The company's ProstACT therapeutic program is assessing the efficacy of the firm's prostate-specific membrane antigen- (PSMA-) aimed at lutetium-177 (177Lu)-labelled therapeutic antibody, TLX591, in various stages of prostate cancer, from first recurrence to advanced metastatic disease.

The TARGET study, a collaboration between Telix and research partner, GenesisCare, is exploring the potential of TLX591 in combination with external radiation in patients at an earlier stage in their prostate cancer, providing direction for future indication expansion. The study, which targets enrolment of 50 patients across multiple Australian sites, enrolled the first patient at GenesisCare's integrated cancer centre at the St John of God Hospital Murdoch campus in Western Australia. The clinical trial is being run through GenesisCare's global Contract Research Organisation and its Australian network of dedicated theranostics centres.